Chris Hillis: Reflections on My Term as President of the Canadian Hematology Society
Chris Hillis, Associate Professor at McMaster University, Former President of the Canadian Hematology Society, shared on LinkedIn:
”Sharing my reflection as I finish my term as President of the Canadian Hematology Society.
Hematology is, in many ways, a microcosm of medicine at its best.
It spans the full spectrum, from rare benign disorders to complex malignancies, from transfusion medicine to cutting-edge cellular therapies.
It is a discipline grounded equally in science and humanity, where laboratory insights translate directly to patient lives, often in profound and immediate ways.
Over the past years, it has been a privilege to witness the continued evolution of our field including new therapies, deeper biological understanding, and a growing national community committed to excellence, collaboration, and equity.
What has stood out most, however, is not just the pace of innovation, but the strength of our people.
Across Canada, hematologists are leading: in research, in clinical care, in education, and in advocacy. We are increasingly interconnected, increasingly collaborative, and increasingly intentional about the kind of community we are building.
It is in that spirit that I am especially pleased to pass the torch to Alina Gerrie (The University of British Columbia BC Cancer).
Alina brings a remarkable combination of clinical expertise, academic rigor, and thoughtful leadership.
She represents the best of Canadian hematology.
Alina is deeply grounded in patient care, actively engaged in advancing knowledge, and committed to mentorship and community-building. Her perspective from British Columbia adds further strength to our national voice, and I have no doubt that under her leadership, the Society will continue to grow.
The future of hematology in Canada is extraordinarily bright!
We are entering an era of precision medicine, of increasingly sophisticated therapeutics, and of expanding opportunities to improve outcomes across all domains of our specialty.
At the same time, we are being called to lead in new ways.
As hematologist we must address access, support trainees and early-career colleagues, and ensure that our systems evolve alongside our science.
I leave this role with confidence that CHS is well-positioned to meet these challenges and opportunities.
That confidence rests not only in Alina’s leadership, but in all of you who continue to define what it means to be a hematologist in Canada.
Thank you for the privilege of serving this community.
I look forward to supporting CHS in new ways and to watching its continued evolution in the years ahead.”
Stay updated with Hemostasis Today.
-
Oct 21, 2026, 00:58Anees Ur Rahman: Completing a Two-Week Clinical Rotation at Haemophilia Treatment Centre Rawalpindi
-
Oct 21, 2026, 00:56Caitlyn Mooney: Pulmonary Embolism in Athletes, Recognition and Return to Sport
-
Oct 21, 2026, 00:54Hani Karrar: Pleased to Share Our Review on Emicizumab in Hemophilia A Management
-
Oct 21, 2026, 00:53Akshay Sharma: HSCT Leads to Sustained Improvements in Sickle Cell Cardiomyopathy for Up to 3 Years
-
Oct 21, 2026, 00:51Prateek Meena: The F. A. T. R. N. Mnemonic for Recognizing TTP
-
Oct 20, 2026, 23:51Registration Is Open for WFH CCS 2027 – World Federation of Hemophilia
-
Oct 20, 2026, 23:44Edward Lee Carter: AF in Nursing Homes – When Stroke Risk Scores Tell Only Part of the Story
-
Oct 20, 2026, 22:59Building Effective Patient Advocacy Through Collaboration Between Patients and Clinicians – EHC
-
Oct 20, 2026, 21:22Intezar Mehdi: When Prolonged Bleeding May Indicate an Underlying Bleeding Disorder